Navigation Links
Regado Biosciences, Inc. to Present at the BIO-Europe Spring® 2012 Conference in Amsterdam, The Netherlands
Date:3/14/2012

BASKING RIDGE, N.J., March 14, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the BIO-Europe Spring® 2012 conference at 9:15 a.m. local time (3:15 a.m. EDT) on March 21, 2012 at the Amsterdam RAI Convention Center in Amsterdam, The Netherlands.

The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the groundbreaking results of the REG1 phase 2b trial (RADAR).  Additionally, a summary of the positive results of the FDA end-of-phase 2 meeting and a description of the resulting phase 3 development program and timeline, minimized for cost and maximized for probability of success, will be provided.

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely and concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, provide a safe and unique approach to personalized medicine.

'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
2. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
3. Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
4. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
5. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
6. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
7. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
8. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
11. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak ... has developed APLS ® Body Guard Bio, ... the spread of bacteria and virus while protecting ... Body Guard Bio features a rugged, external nylon ... that create a leak-proof inner chamber that contains ...
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... 22, 2014   Surefire Medical , Inc., the ... to maximize targeted delivery of embolization agents in minimally ... oncologist John R. Daniels , MD of the ... surgical oncologist Steven C. Katz , MD of ... Scientific Advisory Board (SAB).    "The role ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... CEL-SCI Corporation,(NYSE: CVM ) announced today that ... with the National Institutes of Health Clinical Center,(NIHCC) ... M.D., to,investigate the molecular basis of changes to ... Dr. Marincola is the Chief of,the Infectious Disease ...
... Scientific Meeting -, ORLANDO, Fla., Oct. 7 ... Laboratories,Inc. (NYSE: FRX ) today announced the ... linaclotide,s safety and efficacy in 420 patients with,irritable ... data,indicates that once- daily oral dosing of linaclotide, ...
Cached Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/22/2014)... By Dennis Thompson HealthDay ... freelance cameraman who was diagnosed with Ebola while working for ... system and can leave the special isolation unit at Nebraska Medical ... two weeks, the hospital said Tuesday. A blood test confirmed ... Ashoka Mukpo, 33, can head home to Providence, R.I., NBC ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... 7 (HealthDay News) -- Imaging scans show that chronic daily ... brain, according to a new report. In the study, ... decrease in the number of receptors involved in a wide ... coordination, pleasure, pain tolerance, memory and appetite. Marijuana, also ...
... News) -- Increasing out-of-pocket expenses forces many cancer patients ... appointments and to cut back on food and other ... at 216 cancer patients who sought help from the ... expensive medications. All but one patient had insurance, two-thirds ...
... June 7 (HealthDay News) -- People who have hip or ... are at greater risk for serious complications after the procedure, ... patients at hospitals with low surgical volume, as were deaths ... published online June 7 in Arthritis & Rheumatism . ...
... engineer will test parts of Galveston Bay for toxic ... the best way to handle those pollutants., Hanadi Rifai ... Texas Commission on Environmental Quality (TCEQ) grant that is ... for similar research in the Houston Ship Channel. The ...
... objects, sounds, smells and events: far too much for us ... automatically be snagged by something startling, such as a slamming ... important to us right then, such as locating our child ... also know that people are hard-wired to seek out and ...
... HealthDay Reporter , TUESDAY, June 7 (HealthDay News) -- ... it? A new study suggests that might be a good ... a game when they got some shut-eye afterward. The research ... it does provide more evidence that your brain doesn,t just rest ...
Cached Medicine News:Health News:Chronic Pot Smoking Affects Brain Chemistry, Scans Show 2Health News:Cancer Patients Struggle as Drug Costs Soar: Study 2Health News:Joint Replacement Risks Rise at Less Experienced Hospitals 2Health News:University of Houston researcher receives grant to study water pollutants 2Health News:Your attention please: 'Rewarding' objects can't be ignored 2Health News:Your attention please: 'Rewarding' objects can't be ignored 3Health News:Sleep Might Help You Solve Problems Better 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: